Novel Therapy for Inflammatory Bowel Disease
Loading...
Date
2023
Journal Title
Journal ISSN
Volume Title
Type
Other
Publisher
October university for modern sciences and arts
Series Info
Biochemistry Graduation Project 2022 - 2023;
Doi
Scientific Journal Rankings
Abstract
Irritable bowel disease (IBD) is episodes of inflammation in the gastrointestinal tract, these episodes is
caused by abnormal immune response to gut microflora. IBD is divided into two types: ulcerative
colitis and crohn’s disease. The causes of IBD are increased permeability of intestinal barrier and
imbalance in gut microbiota. Treatment known for IBD are anti-inflammatory drugs like
corticosteroids and sulfasalazine, Immunosuppressive drugs like Imuran. Probiotics are foods or
supplements that contain live microorganisms intended to maintain or improve normal microflora in
the body. Therefore, the aim of study is investigation the efficacy of a novel strain of probiotics to be
used as a potential treatment for IBD. While, the objectives are induction of inflammation on rats and
mice, evaluation of novel therapeutic agent, and assessment of its anti-inflammatory activity
histopathologically and by measuring inflammatory biomarkers. We worked on 3 colitis models: first
model is BALB/c mice and colitis are induced by shigella toxin, second and third models are Wister
albino rats and colitis is induced in one of them by acetic acid and in the other by dextran sulfate. We
made protection with our novel therapy (lactobacillus) and commercial drug (enterogermina) or
sulfasalazine. After the induction step, all mice and rats were scarified, and blood samples were
collected to measure inflammatory biomarkers by ELISA and Western blotting, also intestine is
isolated to be examined histopathologically. Histopathological examinations of acetic acid and Shigella
models showed normal mucosa without alteration in the groups protected by lactobacillus,
sulfasalazine and in control group, while the group protected by enterogermina showed mild edema.
Elisa results proved that lactobacillus has anti-inflammatory activity as it showed inhibition in levels of
inflammatory biomarkers after induction by acetic acid and shigella. In conclusion, lactobacillus
showed more anti-inflammatory activity than enterogermina, so it is a promising drug in IBD
treatment.
Description
Keywords
October University For Modern Sciences and Arts, MSA, October University For Modern Sciences and Arts MSA, جامعة اكتوبر للعلوم الحديثة والاداب, Pathophysiology, Epidemiology, Gut microbiota
Citation
Faculty Of Pharmacy Graduation Project 2022 - 2023